These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

753 related articles for article (PubMed ID: 26120069)

  • 1. Role of BRAF V600E mutation as an indicator of the extent of thyroidectomy and lymph node dissection in conventional papillary thyroid carcinoma.
    Kim SK; Woo JW; Lee JH; Park I; Choe JH; Kim JH; Kim JS
    Surgery; 2015 Dec; 158(6):1500-11. PubMed ID: 26120069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predicting Factors for Bilaterality in Papillary Thyroid Carcinoma with Tumor Size <4 cm.
    Kim SK; Park I; Woo JW; Lee JH; Choe JH; Kim JH; Kim JS
    Thyroid; 2017 Feb; 27(2):207-214. PubMed ID: 27750022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic lymphocytic thyroiditis and BRAF V600E in papillary thyroid carcinoma.
    Kim SK; Woo JW; Lee JH; Park I; Choe JH; Kim JH; Kim JS
    Endocr Relat Cancer; 2016 Jan; 23(1):27-34. PubMed ID: 26598713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of BRAF V600E Mutation and MicroRNA Expression with Central Lymph Node Metastases in Papillary Thyroid Cancer: A Prospective Study from Four Endocrine Surgery Centers.
    Han PA; Kim HS; Cho S; Fazeli R; Najafian A; Khawaja H; McAlexander M; Dy B; Sorensen M; Aronova A; Sebo TJ; Giordano TJ; Fahey TJ; Thompson GB; Gauger PG; Somervell H; Bishop JA; Eshleman JR; Schneider EB; Witwer KW; Umbricht CB; Zeiger MA
    Thyroid; 2016 Apr; 26(4):532-42. PubMed ID: 26950846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of occult central lymph node metastasis in papillary thyroid carcinoma by preoperative BRAF analysis using fine-needle aspiration biopsy: a prospective study.
    Joo JY; Park JY; Yoon YH; Choi B; Kim JM; Jo YS; Shong M; Koo BS
    J Clin Endocrinol Metab; 2012 Nov; 97(11):3996-4003. PubMed ID: 22930785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The synergic effect of BRAF
    Qu HJ; Qu XY; Hu Z; Lin Y; Wang JR; Zheng CF; Tan Z
    Endocr J; 2018 Jan; 65(1):113-120. PubMed ID: 29070763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of lymph node metastases identified on central neck dissection (CND) on the recurrence of papillary thyroid cancer: potential role of BRAFV600E mutation in defining CND.
    Alzahrani AS; Xing M
    Endocr Relat Cancer; 2013 Feb; 20(1):13-22. PubMed ID: 23132792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRAF V600E mutation independently predicts central compartment lymph node metastasis in patients with papillary thyroid cancer.
    Howell GM; Nikiforova MN; Carty SE; Armstrong MJ; Hodak SP; Stang MT; McCoy KL; Nikiforov YE; Yip L
    Ann Surg Oncol; 2013 Jan; 20(1):47-52. PubMed ID: 22941165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors for central lymph node metastasis in patients with papillary thyroid carcinoma: a retrospective study.
    Du J; Yang Q; Sun Y; Shi P; Xu H; Chen X; Dong T; Shi W; Wang Y; Song Z; Shang X; Tian X
    Front Endocrinol (Lausanne); 2023; 14():1288527. PubMed ID: 38047112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Relationship and clinical significance between mutated BRAF with prophylactic central-neck nodal dissection in papillary thyroid carcinoma].
    Zhang YJ; Liu BG; Zhao ZY; Sheng JD; Feng DD
    Beijing Da Xue Xue Bao Yi Xue Ban; 2016 Jun; 48(3):502-6. PubMed ID: 27318915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation among the BRAF gene mutation status, clinicopathological features of primary tumour, and lymph node metastasizing of papillary thyroid carcinoma.
    Lukas J; Drabek J; Dudesek B; Vazan P; Stranska J; Jancik S; Mackova M; Syrucek M; Lukas D; Duskova J; Dundr P; Hintnausova B; Jiskra J
    Exp Clin Endocrinol Diabetes; 2014 May; 122(5):268-72. PubMed ID: 24839220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRAF(V600E) Mutation is Associated with Decreased Disease-Free Survival in Papillary Thyroid Cancer.
    Fraser S; Go C; Aniss A; Sidhu S; Delbridge L; Learoyd D; Clifton-Bligh R; Tacon L; Tsang V; Robinson B; Gill AJ; Sywak M
    World J Surg; 2016 Jul; 40(7):1618-24. PubMed ID: 27138882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRAF V600E mutation: Differential impact on central lymph node metastasis by tumor size in papillary thyroid carcinoma.
    Kim SK; Lee JH; Woo JW; Park I; Choe JH; Kim JH; Kim JS
    Head Neck; 2016 Apr; 38 Suppl 1():E1203-9. PubMed ID: 26268700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrating BRAF
    Zhang Z; Zhang X; Yin Y; Zhao S; Wang K; Shang M; Chen B; Wu X
    BMC Cancer; 2022 Apr; 22(1):461. PubMed ID: 35473554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRAF mutation in fine-needle aspiration specimens as a potential predictor for persistence/recurrence in patients with classical papillary thyroid carcinoma larger than 10 mm at a BRAF mutation prevalent area.
    Moon HJ; Kim EK; Chung WY; Shin DY; Kwak JY
    Head Neck; 2015 Oct; 37(10):1432-8. PubMed ID: 24838814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytomorphological factors and BRAF mutation predicting risk of lymph node metastasis in preoperative liquid-based fine needle aspirations of papillary thyroid carcinoma.
    Chung SY; Lee JS; Lee H; Park SH; Kim SJ; Ryu HS
    Acta Cytol; 2013; 57(3):252-8. PubMed ID: 23636013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predicting factors of central lymph node metastasis and BRAF
    Zhou SL; Guo YP; Zhang L; Deng T; Xu ZG; Ding C; Sun WC; Zhao YW; Kong LF
    World J Surg Oncol; 2021 Jul; 19(1):211. PubMed ID: 34256769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma.
    Kim TY; Kim WB; Rhee YS; Song JY; Kim JM; Gong G; Lee S; Kim SY; Kim SC; Hong SJ; Shong YK
    Clin Endocrinol (Oxf); 2006 Sep; 65(3):364-8. PubMed ID: 16918957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The BRAF(V600E) mutation influences the short- and medium-term outcomes of classic papillary thyroid cancer, but is not an independent predictor of unfavorable outcome.
    Russo M; Malandrino P; Nicolosi ML; Manusia M; Marturano I; Trovato MA; Pellegriti G; Frasca F; Vigneri R
    Thyroid; 2014 Aug; 24(8):1267-74. PubMed ID: 24787545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrating US-guided FNAB, BRAF
    Ma N; Tian HY; Yu ZY; Zhu X; Zhao DW
    Eur Arch Otorhinolaryngol; 2023 Dec; 280(12):5565-5574. PubMed ID: 37540271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.